Published in Gynecol Oncol on May 01, 2002
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology (2010) 0.99
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol (2015) 0.91
Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer. Medicine (Baltimore) (2016) 0.75
Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers. Cancers (Basel) (2016) 0.75
Evaluating the presence of antibodies to HPV as prognostic markers in cervical cancer patients. Gynecol Oncol (2003) 0.75
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med (2007) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Should donors be allowed to give broad consent to future biobank research? Lancet Oncol (2006) 4.30
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer (2005) 3.51
Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst (2008) 3.24
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Consumption of vegetables and fruits and risk of breast cancer. JAMA (2005) 3.02
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Prospective study of hyperglycemia and cancer risk. Diabetes Care (2007) 2.89
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Ethical framework for previously collected biobank samples. Nat Biotechnol (2007) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun (2006) 2.41
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40
Seroepidemiology of the human polyomaviruses. J Gen Virol (2003) 2.32
Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst (2009) 2.32
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ (2014) 2.27
Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res (2008) 2.24
The individual blood cell telomere attrition rate is telomere length dependent. PLoS Genet (2009) 2.17
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis (2012) 2.05
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst (2013) 1.99
Screening and cervical cancer cure: population based cohort study. BMJ (2012) 1.99
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res (2007) 1.82
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Global proficiency study of human papillomavirus genotyping. J Clin Microbiol (2010) 1.78
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet (2010) 1.74
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine (2010) 1.67
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res (2005) 1.66
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol (2008) 1.62
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine (2011) 1.61
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Reproductive tract infections in rural women from the highlands, jungle, and coastal regions of Peru. Bull World Health Organ (2004) 1.54
Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas. J Med Virol (2006) 1.54
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis (2007) 1.54
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol (2006) 1.53
Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer (2004) 1.52
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol (2007) 1.51
Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res (2012) 1.49
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. J Invest Dermatol (2004) 1.48
Epidemiology of Kaposi's Sarcoma herpesvirus (HHV8) in Västerbotten County, Sweden. J Med Virol (2006) 1.47
Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer (2002) 1.47
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis (2008) 1.45
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr (2009) 1.45
Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureus. Carbohydr Res (2003) 1.44
Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control (2002) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology (2013) 1.44
A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer (2002) 1.43
Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models. Antimicrob Agents Chemother (2003) 1.43
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol (2009) 1.40
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine (2013) 1.39